NCT01859143 - Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

InfluenzaHealthy

Interventions

BIOLOGICAL

Trivalent Influenza Vaccine

A single dose of 10\^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.

OTHER

Placebo

A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.

Trial Locations (3)

Research Site, Miami

Research Site, Stockbridge

Research Site, Portland